ERIC Simpson, MD

Dr. Simpson is a professor, and the Frances J. Storrs, MD, is the endowed chair of the Department of Dermatology at OHSU. Dr. Simpson’s clinical training is in pediatric dermatology to treat AD patients. He is a physician-scientist with a research program focusing on AD, including primary and secondary prevention, understanding disease burden, and developing and testing novel outcome measures. He has helped develop and guide AD studies of novel therapeutics, including small molecules and biologic therapies. He was the lead international investigator and Chair of the Steering Committee for the successful Phase 2b and Phase 3 trial of IL4/IL13 antibody Dupilumab for AD and several other AD therapeutic trials that moved to FDA approvals, including the first topical JAK inhibitor ruxolitinib. He has served as consultant or Key Opinion Leader for dermatological drug companies, including AbbVie, Amgen, Arena, BenevolentAI Bio Limited, BiomX Ltd, Bluefin Biomedicine Inc, Boehringer Ingelheim, Eli Lilly, Evidera, ExcerptaMedica, Forte Bio RX, Incyte, Janssen, Kyowa Kirin Pharmaceutical Development, Leo Pharm, Medscape LLC, Novartis, Ortho Dermatologics, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron, Roivant, Sanofi Genzyme, SPARC India, and Valeant. He also consulted for biotech startups Collective Acumen LLC (CA), Coronado, and Dermira.